Initial public issue of 14,53,800 equity shares of face value of Rs. 10/- each ("The Equity Shares") of Avience Biomedicals Limited ("The Company" or "ABL" or The "Issuer") at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 30.24 Crores ("Public Issue") out of which 82,200 equity shares of face value of Rs. 10 each, at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 1.71 Crores will be reserved for subscription by the market maker to the issue (The "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 13,71,600 equity shares of face value of Rs. 10 each, at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 28.53 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.50% and 25.01% respectively of the post-issue paid-up equity share capital of the company. Price Band: Rs. 208/- per equity share of face value Rs. 10/- each. The floor price is 20.8 times the face value of the equity. Bids can be made for a minimum of 600 equity shares and in multiples of 600 equity shares thereafter.